A validated in-house assay for HIV drug resistance mutation surveillance from dried blood spot specimens

被引:1
|
作者
Neufeld, Bronwyn [1 ]
Munyuza, Chantal [1 ]
Reimer, Alexandria [1 ]
Capina, Rupert [1 ]
Lee, Emma R. [1 ]
Becker, Marissa [2 ,3 ]
Sandstrom, Paul [1 ]
Ji, Hezhao [1 ,2 ]
Cholette, Francois
机构
[1] Natl Sexually Transmitted & Blood Borne Infect Lab, Natl Microbiol Lab, Publ Hlth Agcy Canada, JC Wilt Infect Dis Res Ctr, 745 Logan Ave, Winnipeg, MB R3E 3L5, Canada
[2] Univ Manitoba, Max Rady Coll Med, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada
[3] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB, Canada
基金
美国国家卫生研究院;
关键词
HIV; Drug resistance; Dried blood spots; Surveillance; GENOTYPING ASSAY; VIRAL LOAD; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; FIELD-EVALUATION; SUBTYPE-B; GENOMES; AFRICA; PLASMA; PCR;
D O I
10.1016/j.jviromet.2024.114939
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Despite increasing scale-up of antiretroviral therapy (ART) coverage, challenges related to adherence and HIV drug resistance (HIVDR) remain. The high cost of HIVDR surveillance is a persistent challenge with implementation in resource-constrained settings. Dried blood spot (DBS) specimens have been demonstrated to be a feasible alternative to plasma or serum for HIVDR genotyping and are more suitable for lower resource settings. There is a need for affordable HIVDR genotyping assays which can amplify HIV-1 sequences from DBS specimens, particularly those with low viral loads, at a low cost. Here, we present an in-house assay capable of reliably amplifying HIV-1 protease and partial reverse transcriptase genes from DBS specimens, which covers the complete World Health Organization 2009 list of drug resistance mutations under surveillance. DBS specimens were prepared using whole blood spiked with HIV-1 at concentrations of 10,000, 5000, 1000, and 500 copies/mL (n=30 for each concentration). Specimens were tested in triplicate. A two-step approach was used consisting of cDNA synthesis followed by nested PCR. The limit of detection of the assay was calculated to be approximately 5000 (95 % CI: 3200-10,700) copies/mL for the protease gene and 3600 (95 % CI: 2200-10,000) copies/mL for reverse transcriptase. The assay was observed to be most sensitive with higher viral load specimens (97.8 % [95 % CI: 92.2-99.7]) for both protease and reverse transcriptase at 10,000 copies/mL with performance decreasing with the use of specimens with lower viral loads (46.7 % [36.1-57.5] and 60.0 % [49.1-70.2] at 500 copies/mL for protease and reverse transcriptase, respectively). Ultimately, this assay presents a promising opportunity for use in resource-constrained settings. Future work should involve validation under field conditions including sub-optimal storage conditions and preparation of DBS with fingerprick blood in order to accurately reflect real-world collection scenarios.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Stability of Dried Blood Spots for HIV-1 Drug Resistance Analysis
    Hearps, Anna C.
    Ryan, Claire E.
    Morris, Lisa M.
    Plate, Megan M.
    Greengrass, Vicki
    Crowe, Suzanne M.
    CURRENT HIV RESEARCH, 2010, 8 (02) : 134 - 140
  • [42] MULTIPLEX PCR FOR SIMULTANEOUS DETECTION OF HIV AND HCV FROM DRIED BLOOD SPOT
    Cimatti, L.
    De Crignis, E.
    Zecchi, L.
    Gibellini, D.
    Re, M. C.
    INFECTION, 2009, 37 : 96 - 96
  • [43] Evaluation of dried blood spots for HIV-1 drug resistance testing
    García-Lerma, JG
    McNulty, A
    Jennings, C
    Bennett, D
    Fitzgibbon, J
    Morack, R
    Ussery, M
    Folks, TM
    Kalish, ML
    Heneine, W
    ANTIVIRAL THERAPY, 2005, 10 : S49 - S49
  • [44] Evaluations of an in-house drug resistance method for HIV-1 drug resistance using ViroSeq™ 2.0 genotyping system as a gold standard
    Chaturbhuj, Devidas N.
    Deshmukh, Pravin S.
    Hingankar, Nitin K.
    Siddhaarth, K.
    Deshpande, Sohan N.
    Sen, Sourav
    Kabra, Sandhya
    Paranjape, Ramesh S.
    Tripathy, Srikanth P.
    JOURNAL OF VIROLOGICAL METHODS, 2013, 189 (01) : 87 - 92
  • [45] Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance
    Wei, Xierong
    Youngpairoj, Ae S.
    Garrido, Carolina
    Zahonero, Natalia
    Corral, Angelica
    de Mendoza, Carmen
    Heneine, Walid
    Johnson, Jeffrey A.
    Garcia-Lerma, Gerardo
    JOURNAL OF CLINICAL VIROLOGY, 2011, 50 (02) : 148 - 152
  • [46] A PHENYTOIN ASSAY USING DRIED BLOOD SPOT SAMPLES SUITABLE FOR DOMICILIARY THERAPEUTIC DRUG-MONITORING
    COOMBES, EJ
    GAMLEN, TR
    BATSTONE, GF
    LEIGH, PN
    ANNALS OF CLINICAL BIOCHEMISTRY, 1984, 21 (NOV) : 519 - 522
  • [47] Factors determining efficacy of HIV-1 drug resistance genotyping from dried blood spots within an internally-controlled assay system
    Buckton, A. J.
    Bissett, S. L.
    Myers, R. E.
    Beddows, S.
    Pillay, D.
    ANTIVIRAL THERAPY, 2007, 12 : S159 - S159
  • [48] Factors determining efficacy of HIV-1 drug resistance genotyping from dried blood spots within an internally-controlled assay system
    Buckton, A. J.
    Bissett, S. L.
    Myers, R. E.
    Beddows, S.
    Pillay, D.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S159 - S159
  • [49] Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing
    Ji, Hezhao
    Liang, Ben
    Li, Yang
    Van Domselaar, Gary
    Graham, Morag
    Tyler, Shaun
    Merks, Harriet
    Sandstrom, Paul
    Brooks, James
    JOURNAL OF VIROLOGICAL METHODS, 2013, 187 (02) : 314 - 320
  • [50] Dried Blood Spot Specimens Are a Suitable Alternative Sample Type for HIV-1 Viral Load Measurement and Drug Resistance Genotyping in Patients Receiving First-Line Antiretroviral Therapy
    Rottinghaus, Erin K.
    Ugbena, Richard
    Diallo, Karidia
    Bassey, Orji
    Azeez, Aderemi
    DeVos, Joshua
    Zhang, Guoqing
    Aberle-Grasse, John
    Nkengasong, John
    Yang, Chunfu
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (08) : 1187 - 1195